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Abstract
Objective and design We examined the role of IL-6 in the
temporal development of cardiac ischemia–reperfusion
injury employing a closed-chest I/R model.
Materials/methods Infarction, local and systemic
inflammation, neutrophil infiltration, coagulation and ST
elevation/resolution were compared between wild-type
(WT) and IL-6-deficient (IL-6-/-) mice after 1 h ischemia
and 0, , 3, and 24 h reperfusion.
Results IL-6 deficiency reduced infarct size at 3 h
reperfusion (28.8 ± 4.5 % WT vs 17.6 ± 2.5 % IL-6-/-),
which reduction persisted and remained similar at 24 h
reperfusion (25.1 ± 3.0 % WT vs 14.6 ± 4.4 % IL-6-/-).
Serum Amyloid A was reduced at 24 h reperfusion only
(57.5 ± 4.9 WT vs 24.8 ± 5.6 ug/ml IL-6-/- mice). Car-
diac cytokines (IL-6, IL-1b and TNFa) peaked at 3 h
reperfusion, but IL-1b and TNFa levels were unaffected by
IL-6 deficiency. Significant neutrophil influx was only
detected at 24 h reperfusion and was similar for WT and
IL-6-/-. Tissue factor peaked at 24 h reperfusion, whereas
fibrin/fibrinogen peaked at 3 h reperfusion and was com-
pletely resolved at 24 h reperfusion; both coagulation
factors were unaltered by IL-6 deficiency. Prolonged ST
elevation was observed during ischemia that completely
resolved for both genotypes at early reperfusion.
Conclusions The data suggest that, in the absence of
major surgical intervention, IL-6 contributes to the devel-
opment of infarct size in the early phase of reperfusion; this
contribution did not depend on neutrophil influx, IL-1b and
TNFa, tissue factor and fibrin.
Keywords Inflammation  IL-6  Closed-chest model 
Ischemia/reperfusion injury  Heart
Introduction
Acute myocardial ischemia–reperfusion (I/R) is associated
with an inflammatory response that may contribute to I/R-
induced injury of the heart [1, 2]. One important pleiotropic
inflammatory mediator that is released quickly upon car-
diac I/R is interleukin (IL)-6 [3, 4]. Clinical studies have
shown that chronically elevated IL-6 levels in blood are
independently associated with acute coronary syndromes,
suggesting an etiologic role for this cytokine in the process
of myocardial injury [5, 6]. However, several pre-clinical
animal studies have refuted IL-6 as major contributor to
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acute cardiac injury. Left ventricular remodeling and sur-
vival after permanent ischemia [7], left ventricular
remodeling after 48 h I/R [8] or infarct size development
after an acute episode of I/R were similar between wild-
type and IL-6-/- mice [9–11]. Recently, Samanta et al.
have shown that IL-6 did contribute to adverse remodeling
at 35 days following I/R [8]. However, these studies per-
formed I/R immediately following the surgical preparative
intervention of chest opening and puncturing of the heart to
allow the ligation of the LAD. This surgical intervention
significantly raises the baseline level of cytokines where-
upon the effects of I/R-induced cytokine production are
studied [12]. In a previous study we demonstrated that
75 % of the inflammatory cytokine response to acute I/R in
such an open-chest model could be ascribed to the chest
opening. In addition, the opening of the chest was associ-
ated with priming of the NLRP3 inflammasome, which
priming was not observable in the closed-chest model [13].
Knowing that effects of inflammatory mediators are highly
dependent on the actual concentration of the cytokine and
the state of the innate immune system (e.g., [1]), it is,
therefore, still unknown whether IL-6 affects acute cardiac
injury in the absence of major surgery, i.e., in a closed-
chest model of cardiac I/R. Such a closed-chest model
better reflects the condition of acute cardiac syndromes as
occurring in AMI patients and/or during PCI procedures,
whereas the open-chest model better mirrors cardiac sur-
gical procedures. Therefore, in the present study we
examined to what extent IL-6 affects acute myocardial I/R
injury in a closed-chest mouse model.
IL-6 belongs with tumor necrosis factor (TNF)a and IL-
1b to the pro-inflammatory cytokines and may, therefore,
contribute to increases in serum amyloid A (SAA) [14] in
the systematic circulation and to neutrophil influx into the
injured cardiac tissue [15]. In addition, it has been sug-
gested that IL-6 contributes to activation of the coagulation
system in experimental models of endotoxemia, due to the
existence of cross-talk between inflammation and coagu-
lation [16, 17]. Such an increased coagulation, when
associated with microvascular thrombosis, is then a possi-
ble mechanism through which IL-6 can increase infarct
size after myocardial ischemia–reperfusion [18]. Possible
changes in coagulation may then impact the resolution of
ischemia during reperfusion due to changes in no-flow
regions within the heart, as reflected by a divergent ST-
segment resolution [19, 20].
In this study we hypothesized that (1) IL-6 contributes to
acute myocardial ischemia–reperfusion injury, and (2) it
does so through alteration in inflammatory pathways and
activation of the coagulation system. We expected to find
smaller infarct sizes in IL-6 deficient mice due to a less
pronounced pro-inflammatory and pro-coagulant effect.
We, therefore, measured infarct sizes, tested pro-
inflammatory cardiac cytokine levels and systemic SAA
levels, used immunohistochemistry to evaluate neutrophil
influx and activation of the coagulation system (tissue
factor and fibrin/fibrinogen), and used ECG analysis as a
surrogate marker of no-flow in a closed-chest mouse model
[21] after 1 h ischemia and , 3 or 24 h reperfusion.
Materials and methods
Animals
IL-6-/- mice were originally generated by Kopf et al. [22].
Eight- to 10-week-old male IL-6-/- mice (backcrossed
onto a C57BL/6 background for at least 6 generations) and
inbred C57BL/6 mice (for controls) (Jackson Laboratory;
Bar Harbor, ME) were used in this study. They were
housed in open topped cages at constant temperature
(21–22 C), humidity (50 ± 10 %) and light cycle (12 h
dark–light). Rodent chow (AM-II 10 mm, Hope Farms,
Woerden, The Netherlands) and drinking water were
available ad libitum. Experiments were approved under
number DIX 228 by the animal ethics committee of the
Academic Medical Center, Amsterdam, The Netherlands,
and comply with US National Institutes of Health or
European Commission guidelines. The flowchart (Fig. 1)
shows the number of mice in each analysis.
Preparative surgery for I/R in closed chest
Stable anesthesia (with stable hemodynamic parameters)
was induced by 10 ml FFM/kg BW i.p. (FFM: Fentanyl-
Fluanisone-Midazolam) [23, 24]. Hypnorm (VetaPharma,
Leeds, UK) contains 0.315 mg Fentanyl citrate/ml and
10 mg Fluanisone/ml. Midazolam (Actavis, Iceland)
contains 5 mg Dormicum/ml. Both Hypnorm and Mida-
zolam were 1:1 diluted in H2O prior to their 1:1 mixing.
Anesthesia was maintained by bolus injections of  times
the initial FFM volume. Paw withdrawal reflex and tail
pinch were used to monitor the adequacy of anesthesia.
After an induction time of 5 min, a preparative surgery was
started as described previously [21]. Briefly, the skin of the
throat was cut to visualize the trachea. The mice were
intubated with an Intramedic PE-90 tube (Becton Dickin-
son, Sparks, Md), and volume controlled ventilated
(CIV101 ventilator, Columbus Instruments, Ohio) with
room air supplied with 40 % O2. Body temperature was
maintained between 36.6 and 37.4 C. Lateral thoracotomy
was performed between the third and fourth rib, while the
rectus abdominis and pectoralis were kept intact and put
aside. The pericardium was locally opened, and a U-ben-
ded 8–0 prolene suture was put under the LAD
approximately 2 mm lower than the tip of the left auricle,
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similarly as reported by Michael et al. [2] and Xu et al.
[25]. The endings were tunneled in parallel through a 2 mm
Intramedic PE-10 tube (Becton Dickinson, Sparks, Md)
and separately brought outside between the adjacent ribs.
The chest was closed under application of gentle pressure
on both sides of the thorax to expel air, and the endings of
the 8–0 prolene suture were hidden s.c. Post-operative
analgesia was induced by 0.1 mg buprenorphine/kg s.c.
(Temgesic, Schering-Plough, Maarssen, The Nether-
lands). Sterile 0.5 ml 0.9 % saline i.p. was administered as
fluid. Mice were allowed to recover in a temperature-
controlled room of 30 C for 1 day and at room tempera-
ture for[8 days.
Ischemia–reperfusion
9–11 days after the preparative surgery, when the inflam-
matory reaction had subsided [12, 21] the mice were re-
anesthetized with FFM, and allowed to freely breathe under
40 % oxygen-supplemented air. ECG (Einthoven lead I)
was recorded by AgCL coated-silver needles. Output sig-
nals were amplified by a custom-made amplifier, sampled
at 1 kHz, and band pass filtered at 100, 50 Hz and DC, and
directly transferred to LabView5.0 (National Instruments,
Austin, TX, USA). The skin was opened over the old scar,
and the LAD (8–0 prolene) sutures were tightened for 1 h
to achieve ischemia as verified by ECG recording. Release
of the sutures, again confirmed by ECG, resulted in
reperfusion. Mice were killed at different time points after
0, , 3, or 24 h reperfusion. Sham-treated mice had
identical surgical procedures as the experimental group
except that the sutures were not pulled. Mice in the 24 h
reperfusion group were administered 0.1 mg buprenor-
phine/kg/s.c. (Temgesic, Schering-Plough, Maarssen, The
Netherlands) after 30 min reperfusion and housed in a
temperature-controlled room of 30 C. All mice were kil-
led after reperfusion under FFM anesthesia.
Blood sampling
After each experiment, the mice were heparinized via the
tail vein (200 Units heparin (Leo Pharma, Breda, Nether-
lands) in 0.2 ml sterile saline) to prevent coagulation in the
tissues [26]. Blood was collected from the vena cava into a
plastic syringe containing 0.1 volume of 3.2 % sodium
citrate. After centrifugation plasma samples were stored at
-80 C until further analysis.
Infarct size
To identify the area at risk (AAR) and area of infarction
(AOI) within the left ventricle of WT and IL-6-/- mice
after 3 and 24 h reperfusion, hearts were subjected to
Evans blue and 2,3,5-triphenyl-tetrazolium chloride (TTC)
staining [2]. Briefly, after exsanguination the chest was
opened via medial section, on the right side of the septum.
The sutures were tied to definitely occlude the LAD. A
23G1 Gauge blunted needle (Becton–Dickinson, Etten-
Leur, The Netherlands) attached to a 2-ml syringe filled
with 4 C cardioplegic solution was cannulated through the
aorta into the LV lumen and attached to the aorta. The heart
was excised from the body and (retrogradely) infused with
cardioplegia to rinse. Next, the needle was attached to a
1-ml syringe and the heart was infused with 50–100 ll 2 %
Evans Blue (Sigma, St. Louis, MO, USA) to negatively
mark the area at risk (AAR). The heart was cooled for
several min at -20 C after infusion of type VII low gel-
ling temperature agarose (Sigma, St. Louis, MO, USA).
The needle was removed and the heart was serially cut into
transverse sections. The first section contained the suture
around the LAD. To differentiate between the viable and
necrotic areas of the myocardium within the AAR, the
three 0.8 mm sections, the apex, and the base of the heart
were soaked between Whatman filter paper and stained by
1.5 % TTC (Sigma-Aldrich, Steinheim, Germany) in
Prep. 1 h
MI/ sham Reperfusion
0/ ½ / 3 / 24 h
<7 days
Prep. MI
Prep. sham ½ h
Prep. MI ½ h
Prep. MI 3 h
Prep. sham 24 h
Prep. MI 24 h
Mice per group
(3) 5 vs 5 
(3) 4 vs 5 
(3) 6 vs 5 
(2) 10 vs 12
(3) 4 vs 5 
(3) 8 vs 8 
Analysis code
# WT vs # IL-6-/-
(2) 12 vs 7 (4) 6 vs 5 
(4) 6 vs 6 (1) 6 vs 8 
(1) 9 vs 8 (4) 7 vs 6 (2) 12 vs 9 
Prep. sham 3 h
(1) Infarct size 
(2) SAA in plasma,
(3) Cytokines tissue/ plasma
(4) Immunohistochemistry
(3) 5 vs 5 
Fig. 1 Flowchart with time
frame, numbers of mice used
and analyses performed
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phosphate buffer for 20 min at 37 C. Each of the sections
was weighed. Area of infarct (AOI), area at risk (AAR),
and left ventricle (LV) (averaged from both sides of a slice)
were assessed using computer-assisted planimetry (NIH
imager, Scion Image, Meyer Instruments, Houston, TX,
USA) to calculate volumes. Two observers blinded for
genotypes and reperfusion times independently scored the
images of the stained sections.
Homogenate preparation
After exsanguinations, hearts were homogenized (1 vol) in
Greenburger lysis buffer (300 mM NaCl, 15 mM Tris,
2 mM MgCl2, 2 mM Triton(X-100), Pepstatin A, Leu-
peptin, Aprotinin (20 ng/ml), pH 7.4) (9 vol). After
centrifugation, the supernatant was frozen at -80 C for
cytokine measurements.
Cytokines (in hearts and plasma), and SAA (in
plasma)
After 24 h reperfusion, IL-6, IL-1b, and TNFa levels were
in duplicate determined in plasma and in supernatants from
control hearts, sham hearts, and from ischemic and non-
ischemic parts (hearts were longitudinally split into two
parts that contained the ischemic area and the area not at
risk to distinguish the local inflammatory responses).
Measurements of IL-6, IL-1b, and TNFa levels (detection
level 0.50; 0.63; and 0.60 ng/mg, respectively) were per-
formed using commercially available ELISA kits (R&D
systems, Abingdon, UK).
SAA levels were singularly determined in remaining
plasmas after 0, , 3, and 24 h reperfusion (detection level
55 ng/ml) (Biosource International, Inc. Camarillo, CA,
USA).
Tissue sampling for histology
and immunohistochemistry
After , 3, and 24 h reperfusion, WT mice and IL-6-/-
were killed by exsanguinations under anesthesia (see para-
graph ‘‘Blood sampling’’). Hearts were taken from the chest,
and transversally cut at the side where the suture was loosely
saved after induction of reperfusion. The apex was removed
and the mid-section was fixed in 4 % paraformaldehyde for
6 h at room temperature, and embedded in paraffin using
automatic embedding equipment (Tissue Tek, Miles Scien-
tific Inc., USA). 4 lm sections were obtained and every 30th
slice was stained with hematoxylin and eosin, which resulted
in 10–13 stained slices a heart.
For immunohistochemistry, the tissue sections were
deparaffinized, rehydrated, and washed with water and PBS.
Endogenous peroxidase activity was blocked by 1.5 % H2O2
in PBS for 30 min at room temperature, and washed in PBS.
Non-specific binding sites were blocked with TENG-T
[10 mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25 % gelatin,
0.05 % (vol/vol) Tween-20, pH 8.0] or 10 % normal goat
serum (Dako, Glostrup, Denmark) for 30 min at RT, and then
washed in PBS. Sections were incubated at 4 C overnight
with the different primary antibodies. The following anti-
bodies were used: Ly6 for neutrophils (Pharmingen, San
Diego, CA, USA), Tissue Factor (1:250 anti-tissue factor) and
fibrin (Biotinylated goat anti-mouse fibrinogen (Accurate
Chemical & Scientific Corporation, Westbury, NY) recog-
nized fibrin/fibrinogen deposition). In each case, controls
were treated with isotypic control IgG. Sections stained for
Ly6G and fibrin were subsequently incubated with HRP
conjugated swine anti rabbit immunoglobulins and enzyme
activity was detected using 3,30-diaminobenzidine-tetra-hy-
drochloride (DAB, Sigma-Aldrich, St. Louis, MO) or
3-amino-9-ethylcarbazole (AEC, Sigma-Aldrich) as a sub-
strate. If the primary antibody was tissue factor, sections were
sequentially incubated with biotinylated swine antirabbit
immunoglobulins (Dako), strep-ABCAP (Dako) and the
Alkaline Phosphatase substrate kit I (Vector). The slides were
mounted in Entallan or glycerin gelatin, respectively, after a
slight hematoxylin (Ly6G), or no counterstaining (TF and
fibrin/fibrinogen) and analyzed.
Image analysis
The hematoxylin and eosin section with the largest visible
I/R damage was the starting point to select 3 adjacent
sections a heart for immunohistochemistry; The number of
Ly-6G-positive cells, and the expression of tissue factor
and fibrin/fibrinogen was investigated in the same areas
and quantified by digital image analysis. In short, stained
sections were scanned using the Philips IntelliSite Ultra
Fast Scanner (Philips Digital Pathology Solutions, Best,
The Netherlands). The mid-left ventricular free wall
(0.33–1.2 mm [2]) was selected (endocardium and peri-
cardium were always excluded) and a digital image was
captured at 109 magnification. The resulting JPG files
were further analyzed in ImageJ (US National Institutes of
Health, Bethesda, MD). Ly6G-positive cells were manually
counted using the ImageJ cell counter and expressed as
number of neutrophils/mm [2]. Tissue factor and fibrin
images were converted to 8-bit grayscale images and the
immunopositivity was measured by setting an intensity
threshold. The immunopositive area was expressed as a
percentage of the total area.
Analysis of the ST-segment
We limited our analysis of the ST-segment changes by
studying randomly 20 WT and 20 IL-6-/- mice. One WT
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mouse and two IL-6-/- mice seemed to have disturbing
electrical noise and were excluded from the data. The
resulting ECG readings of 19 WT and 18 IL-6-/- mice
were averaged over 10 s recordings using software written
in the Matlab (the Mathworks, USA) script language. Time
alignment within a trace was performed using cross cor-
relation with a template derived from a QRS complex.
Because the morphology of the QRS complex changed as a
result of the intervention it was not possible to align the
differently shaped QRS complexes. Alignment of different
traces was, therefore, done using the P-wave. Afterwards,
the QRS complexes were aligned by hand. The amplitude
of the ST-segment above the iso-electric line was measured
20 ms after the start of the QRS complex.
Statistical analysis
All measurements are reported as mean ± SE. All data
(except AOI/AAR, AAR/LV, and AOI/LV) were not nor-
mally distributed, and therefore we opted for non-
parametric testing using the one-way analysis of Kruskal–
Wallis on medians. A P value of less than 0.05 was con-
sidered statistically significant. Statistics were performed
using the Prism software package (GraphPad, San Diego,
CA).
Results
Infarct sizes as demarcated by TTC and Evans blue stain-
ing showed significantly smaller infarcts in IL-6-/- mice
when compared to WT mice after 3 h reperfusion: Fig. 2a
shows infarct sizes of 28.8 ± 4.5 % in WT mice vs
17.6 ± 2.5 % in IL-6-/- mice after 3 h reperfusion. No
further change in infarct size with IL-6 ablation was
observed at 24 h reperfusion, 25.1 ± 3.0 % in WT mice vs
14.6 ± 4.4 % in IL-6-/- mice, indicating that IL-6-medi-
ated effect on infarct development is effective during the
first hours of reperfusion. The difference in infarct size
between genotypes cannot be ascribed to differences in the
area at risk (Fig. 2b). Figure 2c–f shows representative
examples of TTC and Evans blue stainings.
To examine whether inflammation was constricted to the
ischemic part of the heart only, we first compared the non-
ischemic with the ischemic part of the heart for the  and
24 h reperfusion time points only. After  h reperfusion,
cardiac IL-6 levels were already significantly elevated in
the ischemic part of the heart as compared to the non-
ischemic part in WT mice (5.6 ± 1.0 vs 1.7 ± 0.2 lg/mg;
n = 6, respectively), indicating IL-6 to be a fast responder
to cardiac ischemia (data not shown). After 24 h reperfu-
sion cardiac IL-6 was only mildly elevated in the ischemic
part, showing the transient behavior of IL-6 during I/R
(ischemic 3.0 ± 0.2 vs non-ischemic 1.5 ± 0.1 lg/mg;
n = 8) (data not shown). Thus, the lack of increase in IL-6
in the non-ischemic part of the heart throughout the
experiment indicates that I/R-induced inflammation
remains confined to the ischemic part of the heart. Figure 3
demonstrates levels of cardiac cytokines in the ischemic
part of the heart for WT and IL-6-/- mice at different
times of reperfusion. IL-6 levels peaked at 3 h reperfusion,
and were undetectable in IL-6-/- hearts (Fig. 3a). A sim-
ilar time pattern was observed for IL-1b with a peak at 3 h
reperfusion (Fig. 3b). No differences in IL-1b were
observed between WT and IL-6-/- at any time point,
suggesting that IL-6 is without effect on IL-1b levels.
Cardiac TNFa also peaked at 3 h reperfusion, with no
differences in TNFa levels between WT and IL-6-/- mice
at any time of reperfusion (Fig. 3c). Cardiac IL-6, IL-1b
and TNFa levels in ischemic area and the non-ischemic
area were not different in sham groups at 0,  and 24 h
reperfusion (data not shown), indicating that the temporal
Fig. 2 a Infarct sizes in WT
mice and IL-6-/- mice after
3 and 24 h reperfusion. b Area
at risk sizes in WT mice and IL-
6-/- mice after 3 and 24 h
reperfusion. Values are
mean ± SEM; Black bars
represent WT mice; Striped bars
represent IL-6-/- mice.
Numbers in the bars indicate the
number of analyzed samples. c–
f Representative examples of
Evans blue and TTC-stained
hearts of, respectively, WT 3 h,
IL-6-/- 3 h, WT 24 h, and IL-
6-/- 24 h reperfusion
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changes in cytokines were due to the I/R intervention per
se.
Next we examined whether the omission of IL-6 affec-
ted the acute phase protein response, by monitoring the
production of SAA (produced by liver). Plasma SAA levels
after 0 and  h reperfusion in WT (n = 4 and 12) and IL-
6-/- (n = 6 and 12) mice were undetectable. SAA levels
increased significantly in WT mice after 3 h and 24 h
reperfusion and were highest after 24 h reperfusion
(Fig. 4). SAA was also increased at 3 h reperfusion in IL-
6-/- mice, however, in contrast to WT mice, no further
increase in SAA was observed at 24 h reperfusion;
resulting in significantly decreased SAA in IL-6-/- mice at
24 h reperfusion. These data indicate that the production of
the acute phase response protein SAA is partly, but not
solely, dictated by the rise in IL-6.
Having established that IL-6 affected the acute devel-
opment of cardiac infarction and the rise in the systemic
inflammatory marker SAA, we now examined whether IL-
6 plays a role in neutrophil influx and coagulation activa-
tion following cardiac I/R through immunohistochemical
analysis (Fig. 5). Typical examples of staining for neu-
trophil, tissue factor and fibrin/fibrinogen for WT and IL-
6-/- are demonstrated in Fig. 5a–f. The influx of neu-
trophils in our model of closed-chest cardiac I/R shows a
later response as compared to the cytokine response. Influx
of neutrophils at  h was non-detectable, and only very
minimal present at 3 h reperfusion. At 24 h reperfusion
there was a significantly increased influx of neutrophils,
however, this influx was similar between WT and the IL-
6-/- mice (Fig. 5g). Tissue factor was already detectable at
 h of reperfusion and demonstrated a non-significant
increase with prolongation of reperfusion time, without any
significant effect of IL-6 on this development of tissue
factor during reperfusion (Fig. 5h). Finally, immunostain-
ing for fibrin/fibrinogen also revealed the early presence of
this coagulation factor that peaked at 3 h reperfusion, but
completely disappeared at 24 h reperfusion, with no dif-
ferences between WT and IL-6-/- (Fig. 5i). Data suggest
that the cytokine IL-6 is not involved in the early
Fig. 3 Cardiac cytokines, a IL-6, b IL-1b, and c TNFa in the
ischemic part of the heart for WT and IL-6-/- mice at 0, , 3, and
24 h reperfusion. Values are mean ± SEM; ND means undetectable;
*p\ 0.05; black bars represent WT mice; striped bars represent IL-
6-/- mice; numbers in the bars indicate the number of analyzed
samples
Fig. 4 Plasma SAA levels in WT and IL-6-/- mice after 3 and 24 h
reperfusion. Values are mean ± SEM; *p\ 0.05; black bars repre-
sent WT mice; striped bars represent IL-6-/- mice; numbers in the
bars indicate the number of analyzed samples
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recruitment of neutrophils or the activation of the coagu-
lation system in the early reperfusion phase when
employing a closed-chest model of cardiac I/R.
Finally, we applied ECG recording during cardiac I/R
to monitor ST elevation as surrogate marker of degree of
ischemia and successful and complete reperfusion. Fig-
ure 6 shows a summary of the averaged ST-segment
elevation during ischemia, and its resolution during the
early reperfusion phase for WT (Fig. 6a) and IL-6-/-
(Fig. 6b) mice. Pulling of the sutures induced an
immediate ST-segment elevation that peaked after 30 s.
The ST-segment elevation showed a short lasting nor-
malization at 2 min ischemia and increased for a second
time to reach its maximum after 20 min ischemia. The
elevation persisted during the remaining ischemic period.
Releasing of the sutures induced a short episode of
partial ST-segment resolution that lasted approximately
30 s. Next the ST-segments were again elevated at
1 min at a level that was higher than during ischemia.
This temporal increase disappeared within 5 min and the
ST-segment resolution was complete after 30 min for
both WT and IL-6-/- mice. In none of the mice a
secondary rise or re-elevation in ST-segments was
observed during reperfusion.
Fig. 5 Immunohistochemical analysis of the left ventricular wall of
WT (a–c) and IL6-/- (d–f) mice after I/R injury. a, d Neutrophils
(Ly6G) after 24 h reperfusion; b, e tissue factor after 24 h reperfu-
sion; c, f fibrin/fibrinogen after 3 h reperfusion. Bar 100 lm.
Quantitative analysis of neutrophils (g), tissue factor (h) and
fibrin/fibrinogen (i) after , 3, and 24 h reperfusion. Values are
mean ± SEM; black dots represent WT mice; open dots represent IL-
6-/- mice
Fig. 6 Averaged ST-segment (mV) during 60 min ischemia (unin-
terrupted line) and during the early reperfusion phase (interrupted
line) for a WT mice (n = 19) and b IL-6-/- mice (n = 18)
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Discussion
In this study we have demonstrated that IL-6 is one of the
mediating factors that contributes to the development of
cardiac infarct size during the early period (\1 day) of
reperfusion, following an injurious period of cardiac
ischemia in the absence of surgical stress. In addition, our
data suggest that the observed IL-6 effects on acute cardiac
infarction are not mediated through changes in IL-1b,
TNFa, neutrophil influx or an altered activation of the
tissue factor-thrombin pathway.
IL-6 deficiency and cardiac infarct: closed-chest
versus open-chest cardiac I/R models
In our closed-chest model, the absence of IL-6 resulted in
smaller infarcts. These results are in contrast to previous
studies employing the open-chest model of cardiac I/R,
reporting no effect of IL-6 deficiency on infarct size [9,
10]. Previous studies have demonstrated [12, 13] that the
major difference between these models is the enhanced
activation of inflammatory pathways; i.e., the surgical
stress of chest opening resulted in inflammatory priming.
We demonstrated that [75 % of inflammation in the
open-chest model is due to surgery, and not to the actual
cardiac I/R [13]. As such, the open-chest model mimics
the clinical condition of cardiac I/R during CABG pro-
cedures, whereas the closed-chest model mimics the
clinical condition of cardiac I/R during PCI or throm-
bolytic procedures. Thus, these data indicate that under
conditions of an already activated inflammatory back-
ground (due to e.g., surgery in the open-chest model,
sepsis, etc.), the role of a single acute inflammatory
responder such as IL-6 on acute reperfusion injury is not
detectable. Although open-chest studies suggest that
inflammatory pathways/mediators other than IL-6 become
more critical for modulating cardiac I/R injury in these
conditions (e.g., the Nlrp3 inflammasome [13], TLR4 [27,
28]), further studies are necessary to decipher the precise
molecular mechanisms explaining the different outcome
between the open-chest and closed-chest models. Infarct
sizes in closed-chest models are also usually much
smaller (5–30 % of risk area; present study and Durgan
et al. [29]) than infarct sizes in open-chest studies
(35–60 % of risk area), despite the fact that in these
closed-chest models a longer duration of ischemia (45–60
min) is used as compared to the open-chest models
(30 min ischemia). The decreased inflammation in the
closed-chest models is thus associated with a smaller
infarct size as compared to open-chest models, supporting
the concept that inflammation contributes to the acute
infarct development upon reperfusion.
Theoretically, the inflammatory response caused by the
preparative surgery could have a preconditioning effect.
However, since such preconditioning has an early window
(2–3 h) and a delayed window (which begins 12–24 h later
and lasts 3–4 days) of protection [30] that is much shorter
than the 9–11 days pause we had chosen, it is unlikely that
preconditioning could have affected our I/R results in the
closed-chest model.
Inflammatory mediators and I/R-induced acute
cardiac infarction
Inflammation plays a modulating role in cardiac ischemia–
reperfusion, both in the early reperfusion phase during
infarct development and in the post-infarct phase during
cardiac remodeling [31, 32]. Early responder cytokines
such as TNFa and IL-6, localized in resident mast cells and
endothelial cells, are quickly released and increased in
expression upon the early moments of cardiac I/R. How-
ever, their role on modulating infarct size is likely critically
dependent on the precise pathophysiological conditions
present. TNFa knockout mice are reported to have reduced
or unaltered infarct size in the isolated heart or open-chest
model [32]. IL-6-/- mice are now also reported to have
reduced (present study) or unaltered infarct size [9, 10].
Deletion of IL-6 was also reported to protect against acute
kidney I/R [33]. It is becoming increasingly clear that these
cytokines are all part of a larger network of interacting
cytokines that depending on context (e.g., background
inflammation, timing in I/R processes) can activate or
inhibit cell death/survival signaling cascades. One, often
ignored, important context characteristic, concerns the
duration of the ischemic episode; we previously demon-
strated this for the cardioprotective effects of folic acid:
folic acid protected against 25 min ischemia, but not
against 35 min ischemia [34]. Similarly, it was shown that
deletion of the macrophage migration inhibitory factor
protected hearts from 60 min ischemia, but trended to
increase I/R injury with much shorter ischemia [35]. It is,
therefore, also possible that the protection we now describe
with IL-6 deletion following 60 min ischemia is still
commensurate with findings that report no effect of IL-6
deletion following only 30 min ischemia [9, 10]. Literature
indicates that mechanisms contributing to I/R injury differ
depending on the ischemic duration, such that the efficacy
of factors affecting specific mechanisms also depends on
ischemia duration.
For TNFa it has been reported that this cytokine can
indeed directly contribute to cell death [36], however, no
such data can be found for IL-6. It has been reported
that IL-6 induces mitochondrial dysfunction (decreased
ATP production, increased ROS production) in
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adipocytes [37] but, although mitochondria are crucial
mediators of cardiac I/R injury, it is unknown whether
similar IL-6 effects are obtained in myocardial tissue.
We did find decreased amounts of the acute phase
response protein SAA in IL-6-/- mice. It has been
shown that SAA can function as an agonist for the
innate immune receptors TLR2/4 [38, 39], which
receptors are part of the signaling cascades that con-
tribute to acute cardiac infarction [27, 28, 40]. Thus, it is
possible that IL-6 contributes to infarct development
indirectly through activation of TLR cellular pathways.
IL-6 effects on infarct cannot be explained
by neutrophils and coagulation
In an attempt to further examine factors that contribute to
myocardial injury in WT and IL-6-/- mice, we examined
neutrophil influx by histology. It is known from literature
that the induction and release of IL-6 induces the expres-
sion of intercellular adhesion molecule-1 (ICAM-1) on the
myocyte surface in the viable border zone of the infarct
[41]. The etiologic role of released IL-6 in stimulation of
myocyte ICAM-1 was previously demonstrated by others
[42], and binding of neutrophils to ICAM-1 is considered
to be a causal factor in myocyte injury after ischemia [15,
43, 44]. Although we did not quantify ICAM-1 expression
ourselves, neutrophils were uniformly distributed
throughout the previous ischemic area both in WT and IL-
6-/- mice; the influx in time and the distribution were
equal in WT and IL-6-/- mice suggesting that IL-6 is not
important for the early recruitment of neutrophils to
reperfused ischemic tissue. This can be taken as evidence
that the causal pathway IL-6-ICAM-1-neutrophil is not
operational in the present model; alternatively, if opera-
tional in WT mice, it apparently can be bypassed easily by
other cytokines in IL-6-/- mice. In fact, TNFa was shown
previously to induce ICAM-1 and subsequent neutrophil
influx instead of IL-6 or IL-1b [45]. Since TNFa levels
were similar between WT and IL-6-/- mice within the first
24 h reperfusion in our study, this could well explain the
fact that neutrophil influxes appeared to be independent of
IL-6. Most importantly, the similar influx of neutrophils
between WT and IL-6-/- mice negates that neutrophils can
explain the reduced infarction observed in the IL-6-/-
mice. Moreover, the difference in the time course between
infarction (complete at 3 h reperfusion, no further increase
with 24 h reperfusion) and influx of neutrophils (hardly
detectable at 3 h reperfusion, only at 24 h reperfusion) also
makes it rather unlikely that neutrophils contributed to
cardiac infarction in our model. This is commensurate with
current thinking that I/R-induced infarction mostly takes
place during the first 30 min reperfusion, and is dictated by
mechanisms such as opening of the mitochondrial transi-
tion pore, activation of calpains and hypercontractility [46,
47].
Another element in myocardial injury that may be
affected by different IL-6 levels relates to coagulation
activation. IL-6 is known to be an important agonist of
monocytic tissue factor induction in humans and primates,
either directly, or after endotoxin stimulation [16, 17], thus
we expected a role of IL-6 in inducing myocardial tissue
factor and subsequent fibrin formation. In addition, previ-
ous studies using an antibody against tissue factor, active
protein C or active site inhibited factor VIIa demonstrated
reduction in infarcted area, thus demonstrating a possible
causal relationship between coagulation and ischemic
myocardial injury [18, 48, 49]. However, it has recently
been suggested that these anticoagulants may also directly
activate cytoprotective signaling independent of coagula-
tion inhibition [50, 51].
We were unable to detect any differences in the pres-
ence of tissue factor or fibrin at any time of reperfusion
between WT and IL-6-/- mice. A possible reason as to
why IL-6 does not seem to affect coagulation parameters
may be related to the rather low and short-term activation
of coagulation in our closed-chest cardiac I/R model.
Although there is a trend in increased tissue factor at 24 h
of reperfusion, the fibrin data indicate complete disap-
pearance of fibrin at 24 h reperfusion. The fast
disappearance of fibrin suggests resolution of coagulation
at 24 h of reperfusion. This is also indirectly supported by
our ECG monitoring. The ischemia-induced ST elevation
was quickly and equally resolved during reperfusion in
both WT and IL-6-/- mice. It is, therefore, likely that IL-6
exerts its detrimental effects on acute infarct development
through mechanisms other than coagulation activation or
neutrophil action.
In conclusion, our data indicate that IL-6 contributes to
the development of infarction, in a closed-chest model of
cardiac I/R that is associated with attenuated inflamma-
tion as compared to open-chest models. The beneficial
effects of IL-6 deletion on infarction cannot be explained
by modification of other inflammatory mediators, neu-
trophil influx or coagulation activation. The effects of IL-
6 are apparent within the first 3 h of reperfusion, sug-
gesting a more direct, cellular signaling effect of IL-6 on
the cellular mechanism that causes I/R-induced cell death.
The present findings merit a further investigation into
these direct molecular mechanisms of IL-6 related to
cardiac I/R injury.
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